Artikel ; Online: Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.
2022 Band 11, Heft 4
Abstract: Facioscapulohumeral muscular dystrophy (FSHD) is a debilitating muscular dystrophy with a variable age of onset, severity, and progression. While there is still no cure for this disease, progress towards FSHD therapies has accelerated since the ... ...
Abstract | Facioscapulohumeral muscular dystrophy (FSHD) is a debilitating muscular dystrophy with a variable age of onset, severity, and progression. While there is still no cure for this disease, progress towards FSHD therapies has accelerated since the underlying mechanism of epigenetic derepression of the double homeobox 4 ( |
---|---|
Mesh-Begriff(e) | Homeodomain Proteins/metabolism ; Humans ; Muscle, Skeletal/metabolism ; Muscular Dystrophy, Facioscapulohumeral/drug therapy ; Muscular Dystrophy, Facioscapulohumeral/therapy ; Outcome Assessment, Health Care |
Chemische Substanzen | Homeodomain Proteins |
Sprache | Englisch |
Erscheinungsdatum | 2022-02-16 |
Erscheinungsland | Switzerland |
Dokumenttyp | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review |
ZDB-ID | 2661518-6 |
ISSN | 2073-4409 ; 2073-4409 |
ISSN (online) | 2073-4409 |
ISSN | 2073-4409 |
DOI | 10.3390/cells11040687 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.